Bruker (NASDAQ:BRKR) Issues FY 2025 Earnings Guidance

Bruker (NASDAQ:BRKR) updated its FY 2025 earnings guidance on Thursday. The company provided EPS guidance of 2.670-2.720 for the period, compared to the consensus EPS estimate of 2.680. The company issued revenue guidance of $3.5 billion-$3.5 billion, compared to the consensus revenue estimate of $3.6 billion.

Analyst Ratings Changes

Several research firms have recently commented on BRKR. Bank of America upped their price objective on shares of Bruker from $78.00 to $80.00 and gave the company a “buy” rating in a report on Friday, December 13th. Guggenheim reaffirmed a “buy” rating on shares of Bruker in a report on Friday, January 17th. Barclays decreased their target price on shares of Bruker from $69.00 to $65.00 and set an “overweight” rating for the company in a research note on Monday. TD Cowen decreased their target price on shares of Bruker from $72.00 to $70.00 and set a “hold” rating for the company in a research note on Wednesday, November 6th. Finally, Wells Fargo & Company reduced their price objective on shares of Bruker from $78.00 to $75.00 and set an “overweight” rating for the company in a research report on Wednesday, November 6th. Six equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $74.09.

Bruker Price Performance

Shares of Bruker stock traded down $1.01 during trading hours on Thursday, reaching $50.64. 1,827,096 shares of the company’s stock were exchanged, compared to its average volume of 1,566,893. Bruker has a 1 year low of $48.07 and a 1 year high of $94.86. The company has a market capitalization of $7.68 billion, a P/E ratio of 24.35, a price-to-earnings-growth ratio of 3.81 and a beta of 1.16. The business has a fifty day moving average of $57.88 and a two-hundred day moving average of $60.77. The company has a quick ratio of 0.73, a current ratio of 1.66 and a debt-to-equity ratio of 1.24.

Bruker (NASDAQ:BRKR) last released its earnings results on Thursday, February 13th. The medical research company reported $0.76 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.75 by $0.01. Bruker had a net margin of 9.41% and a return on equity of 21.52%. As a group, research analysts predict that Bruker will post 2.4 earnings per share for the current fiscal year.

Insider Transactions at Bruker

In other news, CEO Frank H. Laukien acquired 100,000 shares of the company’s stock in a transaction that occurred on Monday, November 18th. The stock was purchased at an average price of $50.14 per share, with a total value of $5,014,000.00. Following the completion of the acquisition, the chief executive officer now owns 38,439,563 shares of the company’s stock, valued at $1,927,359,688.82. This trade represents a 0.26 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 28.30% of the company’s stock.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.